WSJ -- Eli Lilly is resisting getting caught up in the wave of drug-industry consolidation. After Pfizer-Wyeth, Merck/Schering-Plough and Roche-Genentech, Lilly CEO John Lechleiter told the Financial Times his company isn’t interested in a mega-merger, and he ruled out a tie-up with Bristol-Myers Squibb.
